Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: the pharma industry reacts to the Ukraine situation; a guide to targeted protein degradation; Janssen/Legend’s US pricing and launch plans for Carvykti; Ipsen seeks multiple licensing deals; and the fourth in the Scrip Asks series looks at prospects for therapeutic advances.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 4 March 2022, including: the pharma industry reacts to the Ukraine situation; a guide to targeted protein degradation; Janssen Pharmaceutical Cos./Legend Biotech Corp.’s US pricing and launch plans for Carvykti; Ipsen SA seeks multiple licensing deals; and the fourth in the Scrip Asks series looks at prospects for therapeutic advances.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Biotech CEOs Take Assertive Stance On Ukraine War, While PhRMA Remains More Neutral" - Scrip, 1 Mar, 2022.)
(Also see "Scrip’s Rough Guide To Targeted Protein Degradation" - Scrip, 28 Feb, 2022.)
(Also see "Janssen/Legend Plan Phased US Launch For BCMA-Targeting CAR-T Carvykti" - Scrip, 28 Feb, 2022.)
(Also see "Ipsen Seeks Success Outside Big Pharma's Hunting Grounds" - Scrip, 2 Mar, 2022.)
(Also see "Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances" - Scrip, 1 Mar, 2022.)